Atomoxetine — Strattera — is the non-stimulant first-line option for ADHD. The mechanism is selective norepinephrine reuptake inhibition (NRI) — no SERT effect, no DAT effect on the transporter level. The clinical relevance of NET-only inhibition is that in PFC, NET is the dominant uptake mechanism for both NE and DA. So blocking NET in PFC raises both NE and dopamine, which is the antiADHD effect — without elevating dopamine in nucleus accumbens or other reward regions where amphetamines and methylphenidate act.
- Class
- Selective norepinephrine reuptake inhibitor (NRI)
- Mechanism
- Pure NET reuptake inhibition. Effects in PFC (where NET is dominant uptake mechanism for DA as well as NE — so DA also indirectly increased in PFC).
- Typical dose
- 40-100 mg/day (target 1.2-1.4 mg/kg/day in children)
- Half-life
- ~5 hours (extensive metabolism — slow CYP2D6 metabolizers have prolonged levels)
- FDA indications
- ADHD (children, adolescents, adults)
- Key adverse effects
- Nausea, decreased appetite, fatigue, somnolence/insomnia, irritability, sexual dysfunction in adults, modest BP/HR elevation
Black box: Suicidal ideation in pediatric patients (initial concern from clinical trials)
Non-controlled — no abuse liability, no diversion concerns. Slower onset than stimulants: full effect over 4-6 weeks. Modest effect size vs. stimulants. Useful when: substance use history, family preference for non-controlled, prominent anxiety with ADHD, tics worsening on stimulants.
That mechanistic difference produces the most important atomoxetine property: no abuse liability. Atomoxetine is not a controlled substance. There is no euphoria. There is no addictive potential. For patients with substance use history, substance use risk, or environments where stimulant diversion is a concern, atomoxetine is often the right answer.
Atomoxetine is the first-line non-stimulant for ADHD — a selective norepinephrine reuptake inhibitor with no abuse potential and a slower, more gradual effect.
Mechanism note: Atomoxetine is the non-stimulant of choice when abuse potential must be avoided — the trade-offs are a slower onset (weeks) and a smaller effect size than stimulants.
The trade-off is the onset. Atomoxetine takes 4-6 weeks of consistent daily dosing to reach full effect. The patient who tries it for a week and concludes "nothing happened" gave it an inadequate trial. Counsel the timeline explicitly — different expectations than stimulants which work day one.
Effect size is modest compared to stimulants. Atomoxetine helps; stimulants help more, on average. For patients who can't take stimulants or who specifically benefit from atomoxetine's profile, the modest effect is worth the trade. For patients who tolerate stimulants well, stimulants typically remain first choice.
Other features that shape clinical use: covers attention for the full day with one or two doses (longer duration than IR stimulants); may help comorbid anxiety in some patients (where stimulants can worsen anxiety); may be useful when stimulants worsen tics (though evidence is mixed); pediatric label has a black-box warning for suicidality.
For ADHD with substance use history, structural heart disease, severe stimulant-induced anxiety, or strong family preference for non-controlled, atomoxetine is the first non-stimulant choice.
- Cost
- Generic: ~$30-80/month.
- Generic status
- Generic since 2017.
- Formulary typical
- Generic Tier 1-2. Sometimes PA for adult use.
- Access friction
- No DEA scheduling — easier prescribing than stimulants. Some plans require failed stimulant trial first.
Prescriber tip: For substance use history or controlled-substance avoidance, atomoxetine is the workhorse non-stimulant. Counsel the 4-6 week onset timeline upfront — patient expectations are the most common failure point.